This study was designed to test the hypothesis that high-dose asparaginase consolidation therapy improves survival in pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma. Five hundred and fifty-two patients (357 patients with T cell acute lymphoblastic leukemia (ALL) and 195 patients with advanced stage lymphoblastic lymphoma) were enrolled in POG study 8704 (T-3). Treatment included rotating combinations of high-dose myelosuppressive chemotherapy agents proven to be effective in T cell ALL in other POG group-wide or local institutional protocols (including vincristine, doxorubicin, cyclophosphamide, prednisone, asparaginase, teniposide, cytarabine and mercaptopurine). After achieving a complete remission (CR), patients were randomized to receive or not receive high-dose intensive asparaginase consolidation (25 000 IU/m 2 ) given weekly for 20 weeks by intramuscular injection. Intrathecal chemotherapy (methotrexate, hydrocortisone and cytarabine) was given to prevent CNS disease, and CNS irradiation was used only for patients with leukemia and an initial WBC of Ͼ50 000/l or patients with active CNS disease at diagnosis. CR was achieved in 96% of patients. The high-dose asparaginase regimen was significantly superior to the control regimen for both the leukemia and lymphoma subgroups. Four-year continuous complete remission rate (CCR) for the leukemia patients was 68% (s.e. 4%) with asparaginase as compared to 55% (s.e. 4%) without. For the lymphoma patients, 4-year CCR was 78% (s.e. 5%) with asparaginase and 64% (s.e. 6%) in the controls. The overall one-sided logrank test had a P value Ͻ0.001 favoring asparaginase, while corresponding values were P = 0.002 for ALL and P = 0.048 lymphoblastic lymphoma. Toxicities were tolerable, but there were 18 failures due to secondary malignancies (16 with non-lymphocytic leukemia or myelodysplasia). Neither WBC at diagnosis (leukemia patients) nor lymphoma stage were major prognostic factors. We conclude that when added to a backbone of effective rotating agents, repeated doses of asparaginase during early treatment improve the outcome for patients with T cell leukemia and advanced stage lymphoblastic lymphoma.
Introduction
Lymphoid malignancies can be classified by cell surface antigen phenotype as derived from either T cell or B cell lineage. T cell lymphoblastic malignancies have distinct biochemical, immunologic and clinical features which set them apart from non-T lymphoid malignancies. Acute lymphoblastic leukemia (ALL) of T cell lineage comprises 10-15% of all cases of childhood ALL. [22] [23] [24] [25] Children with advanced stage lympho- blastic lymphoma usually have T lineage disease, and patients with both of these disease entities are at high risk of treatment failure. [26] [27] [28] [29] [30] [31] [32] [33] [34] Initial efforts by the Pediatric Oncology Group (POG) to improve survival in patients with these aggressive T cell lymphoid malignancies used modifications of the Memorial Sloan Kettering LSA 2 L 2 regimen. Improved survival was accomplished in comparison to historical experience, but the overall expectation for cure was still less than 50%. [35] [36] [37] [38] The malignant cells in T cell lymphoblastic lymphoma are indistinguishable from the blasts of T cell ALL. Because of this common biology, and many similar clinical characteristics, the POG adopted the strategy in the mid 1980s of treating patients with T cell ALL and advanced stage lymphoblastic lymphoma on a common therapeutic protocol, separate from patients with B lineage ALL disease. This 'phenotype-specific' treatment approach was designed to exploit the unique biologic features of each diagnostic category in the hope that a superior outcome could be obtained in each subgroup. This study was designed to test the hypothesis that high dose L-asparaginase consolidation improves survival for patients with these T cell lymphoid malignancies.
Patients and methods

Patient selection
Patients with T cell ALL (confirmed by reference laboratories) were eligible if their age was at least 1 and not more than 21 years, and if no prior therapy had been given except for emergency radiation (XRT) to the mediastinum (for respiratory embarrassment) or less than 1 week of vincristine and prednisone. Patients with diffuse lymphoblastic lymphoma (confirmed by central pathology review) were eligible if they were not more than 21 years old, had Murphy stage III or IV disease, 39 and had received no prior therapy except for emergency XRT to the mediastinum or less than 7 days of prednisone therapy (for respiratory embarrassment). Immunophenotyping was not available for most of the lymphoblastic lymphoma patients, and therefore a small number from this group may not have a T lineage phenotype. Informed consent according to local institutional and federal regulatory guidelines was required prior to registration. Of the patients accrued, 357 had T cell ALL and 195 had advanced stage lymphoblastic lymphoma.
Patients were enrolled in the study between May 1987 and January 1992. The cutoff for analysis was October 1995. This date was the pre-planned selection to obtain 4 year followup on nearly all patients. A complete patient accounting 336 For T-ALL the CR rate was 331/343 (96.5%) with two inevaluable for response, while for lymphoblastic NHL, the CR rate was 172/178 (96.6%) with two inevaluable for response. b Randomization was conducted on a callback to the automated telephone registration system. While reminders were issued, the variable time of count recovery following consolidation therapy contributed to the loss of these 19 patients to the study question. 33  42  18  28  Males  124  118  65  56  Caucasian  117  118  65  62  African-American  19  21  10  12  Hispanic  13  13  5  5  Other  7  8  3  4  Unknown  1  0  0  1  Mediastinal mass  100  88  75 appears in Table 1 . Of the 552 patients enrolled, 27 failed to meet the eligibility requirements (primarily because central review failed to confirm T cell ALL in leukemia patients or lymphoblastic histology in lymphoma patients), 22 did not achieve a documented complete remission as required for post CR randomization, and an additional 19 patients were lost for failure to call the automated telephone registration system for randomization. This report is based primarily on the 484 patients (317 T-ALL and 167 advanced lymphoblastic lymphoma) randomized after achieving a CR. Patient demographics by treatment and diagnosis are presented in Table 2 .
Treatment
The treatment regimen (Table 3 ) was designed by merging into an intensive rotating backbone several different drug combinations extracted from Previous POG group-wide or local institution in-house protocols for T cell malignancies. Each combination chosen had been well documented to have activity against newly diagnosed or relapsed T cell ALL or lymphoblastic lymphoma. 7, [40] [41] [42] After an intensive induction and consolidation, continuation consisted of 10 repetitions of a 9 week cycle with three different drug combinations. Total duration of therapy was planned to be 2 years from the time of initiation of treatment. Prophylaxis of the central nervous system was accomplished with triple intrathecal medications (methotrexate, cytosine arabinoside and hydrocortisone) given seven times during induction and consolidation and once with each continuation cycle. Additionally, leukemia patients with an initial WBC greater than 50 000/l received 2400 cGy of cranial irradiation during consolidation. By current standards, this is a high dose, which was chosen because it was the standard dose for POG protocols when this study was written in the mid 1980s. T cell patients are generally older than B precursor patients, and thus would be more resistant to the toxic effects of cranial XRT. Leukemia patients with initial WBC less than 50 000/l had been shown to be at decreased risk for CNS failure in the POG T-2 study, 22, 38 and did not receive radiation therapy unless they had CNS leukemia at diagnosis. All patients who had CNS disease at the time of initial diagnosis received two additional doses of intrathecal medication during induction and consolidation and then received craniospinal irradiation. All patients received three 'standard' doses of L-asparaginase (Elspar; Merck, West Point, PA, USA) during induction (10 000 IU/m 2 ), and those who achieved CR were randomized to receive or not to receive 'high-dose' L-asparag-inase (25 000 IU/m 2 ) i.m. weekly for 20 doses beginning concurrently with the initiation of the continuation phase of therapy. Patients who developed allergy to E. coli L-asparaginase were switched to Erwinia asparaginase at the same dose. Patients and/or their legal guardians signed informed consent according to FDA and local institutional guidelines prior to the initiation of therapy.
Statistical considerations
The major endpoint for all comparisons is the duration of complete continuous remission (CCR): the time from randomization (which occurred after achievement of CR) to the earliest of relapse, second malignancy, death from any cause, or last clinical contact. Failures included relapses, second malignancies and deaths. Comparisons were conducted by the logrank test, stratified where indicated. Complete continuous remission curves were constructed by the method of Kaplan and Meier, 43 with standard errors of Peto and co-workers. 44 Comparisons of treatments for CCR are one-sided, as designated in the protocol, as the management decision for a non-significant difference or for a significantly different result favoring control over L-asparaginase would be identical: dropping L-asparaginase consolidation from future protocols. Prognostic factors and time to second malignancy were analyzed by two-sided logrank tests. To impute an approximate 4 year event-free survival from 4 year CCR, the reader should multiply the 4 year CCR by the CR rate (96.5%). The standard errors are closely approximated by the standard error for CCR.
Since the study was designed for overall outcome and not for outcome within subsets, the overall result should be inferred as holding in all subsets unless a significant difference in the opposite direction is observed.
Results
Induction therapy
As can be seen in Table 1 , complete remission rates for both T cell ALL and advanced stage lymphoblastic lymphoma were over 96%. Induction failures were evenly distributed to early death (11) and resistant disease (11) .
Continuous complete remission
Overall CCR curves are presented in Figure 1a , and by disease (leukemia vs lymphoma) in Figure 1b . The 4 year CCR rates were as follows: for all patients, control 57.8% (s.e. = 3.4%) and asparaginase 71.3% (s.e. = 3.3%); for T cell ALL patients, control 54.5% (s.e. = 4.1%) and asparaginase 67.9% (s.e. = 4.1%); for lymphoblastic lymphoma patients, control 64.4% (s.e. = 6.0%) and asparaginase 78.0% (s.e. = 5.2%). We are 95% confident that the advantage of the asparaginase consolidation is at least 6.8% overall at 4 years.
In previous POG T cell ALL studies, WBC subdivided at 50 000/l was the most significant prognostic indicator. 22, 35, 38 CCR curves for T cell ALL patients in this report divided by WBC cut at 50 000/l (the cut point for inclusion of cranial radiation therapy) are presented in Figure 2 . In the asparaginase-treated patients, there is no evidence of a significant association with outcome. Table 4 provides an accounting of site-specific failures by treatment and diagnosis. As expected, the major site of relapse was the bone marrow, which was involved with 70/87 (36/45) relapses in leukemia patients (control (asparaginase)), and in 16/31 (5/17) relapses for lymphoma patients. There was an excess of second malignancies (primarily acute non-lymphocytic leukemia or myelodysplastic syndrome) on the asparaginase arm (15 vs three on the control arm). Remission deaths were rare (seven total, three on the control arm and four with asparaginase). Treatment comparisons for continuous complete remission overall (most important) and within subgroups of special interest are presented in Table 5 . Power within the smaller subgroups is very limited. Despite the problem of increased second malignancy, the asparaginase arm had a significant advantage in CCR (P Ͻ 0.001 overall, P = 0.002 in T cell ALL, and P = 0.048 in advanced stage lymphoblastic lymphoma). The P value for second malignancy was 0.009 favoring the control arm.
The prognostic significance of white cell count at diagnosis for the leukemia patients is further explored in Table 6 . Overall, white cell count is only marginally significant in this study, and there is no significant predictive value of white count at diagnosis in the experimental arm. WBC retains predictive significance in the control arm. Patients with extremely high white cell counts (Ͼ300 000/l) fared surprisingly well on the asparaginase arm, with 4 year CCR of 58%.
A prognostic significance for stage (stage III vs stage IV) among the lymphoma patients was not observed in this study. CNS involvement at diagnosis did not significantly correlate with prognosis in patients with leukemia or lymphoma. There was no significant difference in either overall CCR or CNS CCR when patients with CNS disease at diagnosis were compared to those who were CNS negative. Age at diagnosis, sex, presence of a mediastinal mass, cytogenetic abnormalities, and ethnicity likewise had no significant correlation with outcome.
Toxicity
Toxicities were significant, but manageable. Allergic reactions were more common on the asparaginase arm with 59/244 (24%) patients reporting allergic reactions vs 24/240 (10%) on the control arm. Almost all of these allergic reactions were local urticarial reactions to the asparaginase injections, and resulted in a switch to the Erwinia asparaginase preparation. There were also allergic reactions reported in association with teniposide doses and antibiotics administered during febrile neutropenic episodes. There were no fatal allergic reactions. Neurotoxicity was similar on the two arms with 28 patients (24 patients) reporting grade 3+ neurotoxicity on the asparaginase arm (control arm), respectively. One patient developed fatal leukoencephalopathy, but the other neurologic toxicities were predominantly single seizure episodes following intrathecal medications or peripheral neuropathy following vincri- 
Figure 2
Comparison of continuous complete remission rates for leukemia patients by white blood count (WBC) subdivided at 50 000/l treated with (ASP) or without (Control) high-dose L-asparaginase consolidation. (For WBC Ͻ50 000 P = 0.15; for WBC Ͼ50 000 P = 0.002.) Table 4 Failures Patients  157  160  83  84  Total failures  90  58  34  24  Relapses  87  45  31  17  Marrow only  54  30 stine administration. Deaths in CR were unusual, accounting for only five failures in the leukemia group (three bacterial sepsis, one Pneumocystis carinii pneumonia and one leukoencephalopathy) and two failures in the lymphoma group (one accidental fall from the roof of a building and one bronchiolitis obliterans). Most patients tolerated therapy with minimal dose reductions, although there were frequent delays due to slow count recovery (G-CSF was not used in this protocol). Delays in therapy were most common after the continuous infusion cytarabine and cyclophosphamide combination in continuation. Other frequently reported toxicities are presented in Table 7 . There was no significant difference in the reported incidence of neutropenia (36% control vs 38% experimental, P = 0.16) or sepsis (1.6% control vs 2.3% experimental, P = 0.083). Thrombocytopenia (2.6% control vs 6.2% experimental, P Ͻ 0.001), liver function abnormalities (transaminase elevation 0.9% control vs 2.6% experimental, P Ͻ 0.001; bilirubin elevation 0.05% control vs 1.2% experimental, P values: Ͻ50 vs Ͼ50: P = 0.037 (overall), P = 0.008 (control), P = 0.57 (L-ASP); Ͻ300 vs Ͼ300: P = 0.009 (overall), P = 0.008
340
Expected to observed values are compared vertically. P Ͻ 0.001) and pancreatitis (amylase elevation 0.10% control vs 0.82% experimental, P Ͻ 0.001) were more commonly reported on the asparaginase arm. There was no reported grade 3 or 4 bleeding or thrombotic events. As previously mentioned, second malignancies also occurred more frequently on the intensive asparaginase regimen, 45 but nonetheless the outcome is superior.
Discussion
T cell lymphoblastic malignancies share a distinct clinical, biochemical, histochemical, cytogenetic and surface antigen phenotype which distinguishes the blast cells from B precursor lymphoid malignancies. Traditionally, the presence of a T cell phenotype has been a poor prognostic feature in acute lymphoblastic leukemia in children, and patients with advanced stage lymphoblastic lymphoma have also been at high risk for relapse. [26] [27] [28] [29] [30] [31] [32] [33] [34] However, intensified therapy has improved the outlook for patients with T cell ALL and advanced stage lymphoblastic lymphoma. [35] [36] [37] [38] T cell ALL patients have fared progressively better with each generation of POG protocols, with a 4 year CCR of 65% on the asparaginase arm of the current study. Non-POG regimens also have resulted in improved survival for patients with T-ALL and advanced stage lymphoblastic NHL. [46] [47] [48] This study demonstrated a significant improvement in event-free survival (EFS) for patients who received high-dose intensive asparaginase consolidation added to an effective rotating backbone. This was particularly striking in the leukemia patients with an initial WBC Ͼ50 000/l, but also was significant in the patients with lymphoma. Early intensive asparaginase is felt to be a key element contributing to improved survival in the Dana Farber Cancer Institute protocol for treatment of patients with T-ALL and advanced stage lymphoblastic NHL. 42, 46 In most studies of T cell leukemia, a higher WBC at diagnosis is an adverse prognostic factor. 22, 35, 38, 49 In the current study, with the addition of intensive asparaginase, WBC lost its prognostic significance. This may have been due in part to the lesser degree of improvement seen in the patients with a low WBC who received asparaginase. The only difference in the therapy between patients with a high or low initial WBC was the inclusion of cranial XRT for CNS prophylaxis in the high WBC group only. The possible role of XRT as a contributing factor in systemic control is of interest because of the differential efficacy of this regimen in patients who received or did not receive cranial XRT in comparison to previous treatment regimens. CNS control was acceptable in all subgroups, with CNS event-free survival greater than 90%.
Secondary malignancies, predominantly non-lymphoid leukemia and myelodysplasia, accounted for a significant subset of the treatment failures. These failures may be related to the use of the epipodophyllotoxin VM-26 in the treatment regimen. The time to development of the secondary malignancies (14 months to 4 years from original diagnosis) and the occurrence of cytogenetic abnormalities at chromosome band 11q23 in seven patients suggests topoisomerase II inhibitorrelated leukemogenesis. [50] [51] [52] [53] [54] Anthracyclines have been implicated in a similar pattern of leukemogenesis, and might also have contributed to these failures. The failures in our study, however, are not suggestive of alkylator-induced secondary malignancies which generally have a longer latent period and cytogenetic abnormalities of chromosome 5 or 7. [55] [56] [57] The use of CNS irradiation had no detectable impact on the development of secondary malignancies.
Of interest, the development of second malignancy as a cause of failure was significantly higher in the experimental arm (P = 0.009, two-sided, see Table 4 ). This was not a prospective hypothesis, however, and should be interpreted with caution. Additional study of this phenomenon is ongoing, and will be the subject of a future report.
The mechanism of the apparent contribution of the asparaginase consolidation to secondary leukemia is not understood, but may involve an interaction with the epipodophyllotoxin VM-26, perhaps by limiting the ability of cells to repair DNA damage by inhibiting synthesis of repair enzymes. The second malignancies were all counted as failures in the analysis, however, and the experimental arm still had a superior outcome. Thus the apparent advantage of the high-dose asparaginase consolidation outweighed the risk of second malignancy in this study. Limiting the use of epipodophyllotoxin in future treatment regimens may decrease the risk of second malignancy acute non-lymphocytic leukemia, and further improve the overall outcome.
Two statistical points are worth mentioning. First, the strategy of randomizing after achievement of a CR caused the loss of 19 patients (who achieved a CR, but the institution failed to randomize them) and 22 patients who never achieved a documented CR. On balance, if randomization had occurred up front, the outcome of those patients not achieving a CR would have been 'pure noise,' since they failed before the divergence of the therapies. From a power perspective, the exclusion of 22 uninformative failures is a much greater gain than the exclusion of 19 CR patients prior to randomization is a loss. The second issue deals with the fact that we have 2 additional years of follow-up beyond the October 1995 cutoff.
Although an analysis at the October 1997 cutoff was not a planned one, it is important to note that the overall conclusions on the basis of the most current information are unchanged. There were only six additional failures in these 2 years (two on the control arm and four on the experimental arm). The overall comparison has P Ͻ 0.001, within T-ALL P = 0.002, and within NHL P = 0.046 all favoring the experimental arm.
The ultimate goal of dividing treatment groups based on lymphoid lineage is that truly lineage-specific therapeutic interventions will be devised. In the absence of truly T-specific therapy, however, the unique biological features of the T cell blasts may result in patterns of responsiveness that differ from other phenotypes. The high-dose intensive asparaginase consolidation which significantly improved survival in this study had no significant impact in a POG study of B precursor ALL. 58 Therefore, even though more intensive treatment regimens have eliminated to a large extent the prognostic significance of the T cell phenotype in childhood, it will remain important to track the results of treatment interventions by phenotype in future trials. The use of intensive asparaginase consolidation should be considered in future treatment regimens for T cell lymphoid malignancies.
